Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Cataract surgery remains one of the most frequently performed and successful surgical procedures worldwide, involving the removal of a clouded natural lens and its replacement with an intraocular lens ...

These studies found that IOL implant errors were due to intraoperative errors including failure to check the lens specifications, a lack of procedure for verification of the correct lens, confusion of ...

Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances.

Launched in the month of World Sight Day, this next-generation monofocal intraocular lens is an advanced solution for post cataract surgery patients, that helps to meet the changing lifestyle needs of ...